Pharma
Merck KGaA presents long-term success with MS medication Mavenclad
Merck achieves significant progress with Mavenclad in the treatment of multiple sclerosis, as presented at the ECTRIMS Congress.
Merck KGaA Reports Success with Their Drug Mavenclad (Cladribine Tablets), Achieving a "Sustained Therapeutic Effect" in People with Relapsing Multiple Sclerosis (RMS).
At the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from September 18 to 20 in Copenhagen, the Darmstadt-based company will present new data on the long-term safety and sustained efficacy of the drug.
In Phase IV studies, Mavenclad demonstrated consistently high safety and efficacy over a period of four years, as reflected, among other things, in improved MRI findings and enhanced cognitive performance of the patients. Particularly noteworthy is that 79.2 percent of the patients showed no evidence of disease activity (NEDA-3 status) in the fourth year of treatment.
Despite the positive results, Merck's stock temporarily lost 0.18 percent in XETRA trading on Thursday, settling at 169.50 euros.
